Anti-inflammatory mediator production

Anti-inflammatory mediator production" is not a single molecule or receptor but refers to the **biosynthetic processes that generate specialized pro-resolving lipid mediators**—including lipoxins (from arachidonic acid), resolvins and protectins (from omega‑3 fatty acids), and maresin 1. These families are produced primarily through enzymatic pathways involving cyclooxygenases and lipoxygenases in immune cells such as macrophages. They act as potent agonists at specific receptors to control the magnitude and duration of acute inflammatory responses. Their functions include stimulating anti-inflammatory cytokine production (e.g., IL‑10), promoting clearance of apoptotic cells by macrophages ("efferocytosis"), facilitating tissue repair after injury or infection, and restoring homeostasis following inflammation. Deficiencies in these resolution pathways may contribute to chronic inflammatory diseases. While drugs like aspirin can enhance the biosynthesis of some anti-inflammatory mediators by modifying enzyme activity ("aspirin-triggered" epimers), "anti-inflammatory mediator production" itself is a process rather than a discrete drug target or molecular entity suitable for direct pharmacological targeting.

Promotion of endogenous lipid mediator synthesis that actively resolves inflammation and restores tissue homeostasis. Agonism at specific pro-resolving receptors by mediators such as lipoxins, resolvins, protectins, maresins.